A5092110327- Dementia and Cognitive Impairment Research
- Alzheimer's disease research and treatments
- Parkinson's Disease Mechanisms and Treatments
- Functional Brain Connectivity Studies
- Advanced MRI Techniques and Applications
- Advanced Neuroimaging Techniques and Applications
Northern California Institute for Research and Education
2023-2024
Abstract INTRODUCTION Alzheimer's disease (AD) pathology is defined by β‐amyloid (Aβ) plaques and neurofibrillary tau, but Lewy bodies (LBs; 𝛼‐synuclein aggregates) are a common co‐pathology for which effective biomarkers needed. METHODS A validated α‐synuclein Seed Amplification Assay (SAA) was used on recent cerebrospinal fluid (CSF) samples from 1638 Disease Neuroimaging Initiative (ADNI) participants, 78 with LB‐pathology confirmation at autopsy. We compared SAA outcomes neuropathology,...
Abstract INTRODUCTION Cerebrospinal fluid (CSF) α‐synuclein (α‐syn) seed amplification assay (SAA) is a sensitive and specific tool for detecting Lewy body co‐pathology in Alzheimer's disease. METHODS A total of 1637 cross‐sectional 407 longitudinal CSF samples from the Disease Neuroimaging Initiative (ADNI) were tested with SAA. We examined dynamics amyloid beta (Aβ), α‐syn seeds, phosphorylated tau181 (p‐tau181), along global domain‐specific cognition stable SAA+, SAA−, those who converted...
CSF α-synuclein seed amplification assay (SAA) is a sensitive and specific tool for detecting Lewy body (LB) co-pathology in AD.
Abstract INTRODUCTION Alzheimer's Disease Neuroimaging Initiative (ADNI) has been pivotal in identifying and refining disease (AD) biomarkers for clinical trials. This study leverages longitudinal data from participants who have progressed to amyloid‐positivity during their participation track evolution of cognitive function. METHODS We modeled AD biomarker (positron emission tomography [PET], structural, cerebrospinal fluid [CSF], cognition) trajectories before after observed onset time...
Abstract INTRODUCTION How to detect patterns of greater tau burden and accumulation is still an open question. METHODS An unsupervised data‐driven whole‐brain pattern analysis longitudinal positron emission tomography (PET) was used first identify distinct profiles then build baseline models predictive tau‐accumulation type. RESULTS The flortaucipir PET from studies done by the Alzheimer's Disease Neuroimaging Initiative, Avid Pharmaceuticals, Harvard Aging Brain Study ( N = 348 cognitively...